ClinicalTrials.gg
CompletedNCT04844983Updated Mar 18, 2024

A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

A Phase 2 interventional study of STP705 and Placebo Saline in Squamous Cell Carcinoma in Situ, sponsored by Sirnaomics. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Sirnaomics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies in Squamous Intraepithelial Lesions with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Squamous Intraepithelial Lesions · United States.

Enrollment
21st of 39
44 · median 48
Started
2021
the only one that year
Phase 2
19 of 44
4 open now
Registered
35th of 44
by date

Among the 44 studies in Squamous Intraepithelial Lesions with a site in United States, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2021, is one of 19 in phase 2, and was the 35th registered.

Squamous Intraepithelial Lesions

104 studies on the registry are indexed under Squamous Intraepithelial Lesions; 36 are open to participants now.

Browse Squamous Intraepithelial Lesions studies →

Open to participants now

7 of the 44 studies in Squamous Intraepithelial Lesions with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Squamous Intraepithelial Lesions studies recruiting now, 11 (48%) set no upper age limit and 11 (48%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Squamous Intraepithelial Lesions with a site in United States, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma (in situ) skin cancer (isSCC).

Read the detailed description

This is a two-part, double-blind, randomized, placebo-controlled study designed to evaluate safety and efficacy of various doses of STP705 administered as an intralesional injection in subjects with isSCC.

A total of up to 100 eligible subjects will be enrolled. Enrolled subjects will be randomly allocated to receive STP705 or placebo injection once weekly for 6 weeks.

After 6 weeks, the lesion will be excised.

In part 1 (dose ranging study): 40 subjects will be randomized to receive 1 of the 3 STP705 doses or placebo.

An interim analysis will be done after all subjects have completed end of treatment (EOT) visits to determine 2 selected dose levels of STP705 to be used in part of the study.

In part 2: 60 additional subjects will be randomized to receive 1 of the 2 selected doses (from part 1) or placebo.

In both parts at the End of Treatment (EOT), the lesion will be excised.

03

Conditions studied

  • Squamous Cell Carcinoma in Situ
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult ≥ 18 years of age.
  2. Primary, confirmed trunk or extremity (non- anogenital/-facial/-scalp) isSCC lesion suitable for excision with a minimum diameter of 0.5 cm and with a maximum diameter of 2.0 cm.
  3. Histological diagnosis made no more than 6 months prior to the screening visit.
  4. No other dermatological disease in the isSCC target site or surrounding area, which in the opinion of the investigator, could interfere with the study.
  5. Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period.
  6. Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study.
  7. Laboratory values for the tests (listed in the Study Schedule) within the reference ranges as defined by the central laboratory, or "out of range" test results that are clinically acceptable to the investigator.
  8. Ability to follow study instructions and likely to complete all study requirements.
  9. Written obtained, including consent for tissue to be examined and stored by the Central Histology Lab.
  10. Written consent to allow photographs of the target isSCC lesion to be used as part of the study data and documentation.
  11. For females of , a negative pregnancy test at screening and using an acceptable form of (oral / implant/ injectable/ transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy).

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, lactating, or planning to become pregnant.
  2. Presence of known or suspected systemic cancer.
  3. Histological evidence of severe squamous metaplasia, infiltrative, desmoplastic or micronodular growth patterns in the specimen.
  4. History of recurrence of the target isSCC lesion.
  5. Concurrent disease or treatment that suppresses the immune system.
  6. Patients with baseline QTC > 480 msec using Frederica's formula.
  7. Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk.
  8. Known sensitivity to any of the ingredients in the study medication including an allergy to trehalose.
  9. Use of a tanning bed or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the study.
  10. Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit.
  11. Use of systemic retinoids within the 6 months prior to the screening period.
  12. Treatment with systemic immunomodulators or within the 6 months prior to the screening period.
  13. Use of topical immunomodulators within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening period.
  14. Treatment with the following topical agents within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening visit: aminolevulinic acid, 5-fluorouracil, , retinoids, diclofenac, ingenol mebutate, or imiquimod.
  15. Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the target isSCC lesion during the 4 weeks prior to the screening visit.
  16. Evidence of current chronic alcohol or drug abuse.
  17. Current enrollment in an drug or device study or participation in such a study within 4 weeks of the screening visit.
  18. In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Part 1: Arm A

    STP705 30 μg dose, intralesional injection, given once a week for 6 weeks.

    Drug: STP705

  • Experimental
    Part 1: Arm B

    STP705 60 μg dose, intralesional injection, given once a week for 6 weeks.

    Drug: STP705

  • Experimental
    Part 1: Arm C

    STP705 90 μg dose, intralesional injection, given once a week for 6 weeks.

    Drug: STP705

  • Other
    Part 1: Arm D

    Placebo (normal saline), intralesional injection, given once a week for 6 weeks.

    Other: Placebo Saline

  • Experimental
    Part 2: Arm A, B or C

    STP705 selected dose 1, intralesional injection, given once a week for 6 weeks.

    Drug: STP705

  • Experimental
    Part 2: Arm A or B or C

    STP705 selected dose 2, intralesional injection, given once a week for 6 weeks.

    Drug: STP705

  • Other
    Part 2: Arm D

    Placebo (normal saline), intralesional injection, given once a week for 6 weeks.

    Other: Placebo Saline

Interventions

  • DrugSTP705

    The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

    Also known as: STP705 Powder for Injection

  • OtherPlacebo Saline

    Normal Saline

06

What researchers measure

Primary outcomes

  1. Proportion of participants with histological clearance of treated isSCC lesion

    Proportion of participants with histological clearance of treated isSCC lesion at the End of Treatment (EOT).

    Time frame: 6 weeks

Secondary outcomes

  1. Change in size of the treated isSCC lesion

    Change in size of the treated isSCC lesion over the 6-week treatment period.

    Time frame: 6 weeks

07

Study locations

7 sites
  • Investigate MD
    Scottsdale, Arizona 85255, United States
  • Center for Clinical and Cosmetic Research
    Aventura, Florida 33180, United States
  • Research Institute of the Southeast LLC
    West Palm Beach, Florida 33401, United States
  • Dermatology, Laser and Vein Specialists of the Carolinas
    Charlotte, North Carolina 28207, United States
  • Dermatology Associates of Knoxville
    Knoxville, Tennessee 37909, United States
  • Tennessee Clinical Research
    Nashville, Tennessee 37215, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Aug 2022, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2021
First posted
Apr 14, 2021
StartActual
May 18, 2021
Primary completionActual
Aug 24, 2022
CompletionActual
Dec 6, 2022
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04844983
Lead sponsor
Sirnaomics
Responsible party
Sponsor
First posted
Apr 14, 2021
Start date
May 18, 2021
Primary completion
Aug 24, 2022
Completion
Dec 6, 2022
Last update
Mar 18, 2024

Study contacts

Mark Nestor, MD
principal investigator · Center for Clinical and Cosmetic Research
David Goldberg
principal investigator · Schweiger Dermatology Group
Michael Gold, MD
principal investigator · Tennessee Clinical Research
Edward Lain, MD
principal investigator · Austin Institute for Clinical Research
Kenneth Beer, MD
principal investigator · Research Institute of the Southeast LLC
Brenda LaTowsky, MD
principal investigator · Investigate MD
Edward Primka, MD
principal investigator · Dermatology Associates of Knoxville
Girish Munavalli, MD
principal investigator · Dermatology, Laser and Vein Specialists of the Carolinas
Brian Jiang, MD
principal investigator · University of California, San Diego
Megan Couvillion, MD
principal investigator · SBA Dermatology
Mark Ling, MD
principal investigator · Medaphase Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cotsiranib

Start the discussion